According to a recent LinkedIn post from Truveta, Truveta Research has released an updated GLP-1 monitoring report covering data through March 2026. The post highlights that GLP-1 therapies accounted for nearly 8% of all prescriptions in March, representing the largest quarter-over-quarter increase since 2019.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post further notes that first-time anti-obesity medication prescribing rose 21.7% from December 2025 to March 2026, with first-time semaglutide use increasing by more than 50%. The post suggests this growth is likely influenced by the approval of the Wegovy pill formulation.
For investors, the data underscores sustained demand momentum for GLP-1 and anti-obesity treatments, signaling continued revenue tailwinds for manufacturers and related value-chain participants. Truveta’s ability to track and publish granular prescription trends may enhance its positioning as a data partner for life sciences firms, payers, and providers seeking real-world evidence.
The emphasis on quarter-over-quarter inflection points indicates that Truveta’s datasets can be used to monitor market share shifts and adoption curves for new formulations. This could strengthen the company’s commercial prospects in analytics, inform pricing and access strategies across the sector, and support subscription or project-based revenue tied to real-world data insights.